<DOC>
	<DOCNO>NCT00478621</DOCNO>
	<brief_summary>Infection human papillomavirus ( HPV ) clearly establish central cause cervical cancer . Indeed , certain oncogenic type HPV infect cervix ( part uterus womb ) . This infection may go away , go away ( call persistent infection ) , lead woman long period time cancer cervix . GlaxoSmithKline Biologicals develop HPV vaccine oncogenic type HPV-16 HPV-18 formulate AS04 adjuvant ( control vaccine ) also evaluate novel HPV vaccine formulation . This study evaluate novel GSK Biologicals ' HPV vaccine ( GSK1674330A ) term safety immunogenicity compare control vaccine . There different level blind study . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Human Papillomavirus Vaccine Safety &amp; Immunogenicity Trial Healthy Young Adult Women With HPV Vaccine ( GSK1674330A )</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>A woman investigator believe comply requirement protocol . A woman , include , 18 25 year age time first vaccination . Written informed consent must obtain subject prior enrolment . Healthy subject establish medical history clinical examination enter study . Subject must nonchildbearing potential , child bear potential , must negative pregnancy test must use adequate contraceptive precaution 30 day prior first vaccination must agree continue precaution two month completion vaccination series . Subject 6 lifetime sexual partner prior enrolment . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use six month last dose vaccine . Concurrently participate another clinical study , time study period ( six month last dose vaccine ) , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose plan study period one month last dose vaccine . Planned administration/administration vaccine foreseen study protocol within 30 day 30 day ( i.e . day 029 ) first dose study vaccine . Planned administration/administration routine vaccine 8 day first dose study vaccine allow . Enrolment defer subject outside specify window . Pregnant breastfeeding . Women must least 3 month postpregnancy breastfeed enter study . A woman plan become pregnant planning discontinue contraceptive precaution study period , two month last vaccine dose . Previous vaccination HPV plan administration HPV vaccine foreseen study protocol study period . Previous administration component investigational vaccine Any medically diagnose suspected immunodeficient condition base medical history physical examination allergic disease , suspect allergy reaction likely exacerbate component study vaccine . Hypersensitivity latex . Known acute chronic , clinically significant pulmonary , cardiovascular , neurologic , hepatic renal functional abnormality , determine previous physical examination laboratory test . Cancer autoimmune disease treatment . History allergic disease , suspect allergy reaction likely exacerbate component study vaccine . History colposcopy plan colposcopy evaluate abnormal cervical cytology test . Received immunoglobulin and/or blood product within 3 month precede enrolment plan administration study period one month last dose vaccine . Enrolment defer subject outside specify window . Acute disease time enrolment . Heavy bleeding ( menstruation ) heavy vaginal discharge cervical sample collect . Enrolment deferred condition resolve accord investigator medical judgement .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HPV</keyword>
</DOC>